What the Law Means by Label, and by Labeling

Answer first: the label is on the container, the labeling can accompany it

The definitions are in 21 U.S.C. 321, and they are short enough to read in full. Subsection (k): "The term 'label' means a display of written, printed, or graphic matter upon the immediate container of any article; and a requirement made by or under authority of this chapter that any word, statement, or other information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any there be, of the retail package of such article, or is easily legible through the outside container or wrapper."

Subsection (m): "The term 'labeling' means all labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article."

The second definition contains the first and then adds two clauses. The one that matters is accompanying such article. That word is why labeling is not limited to anything physically stuck to a bottle, and it is the reason package inserts, leaflets and other materials are analyzed under the same rules as the sticker. There is also a small definition between them that resolves a common ambiguity: "The term 'immediate container' does not include package liners."

This is the foundation under every requirement about what a drug may say, because the misbranding provisions are written in terms of these two words.

The misbranding rule is one sentence long

Section 352 opens: "A drug or device shall be deemed to be misbranded—" and then lists the ways. The first is the shortest and the broadest: "If its labeling is false or misleading in any particular."

In any particular is doing real work. There is no materiality threshold on the face of that clause and no requirement that anyone was actually misled. The paragraph goes on to carve out one specific exception — health care economic information provided to a payor, formulary committee or similar entity with expertise, where the information relates to an approved indication, is based on competent and reliable scientific evidence, and includes a conspicuous statement describing any material differences from the approved labeling. That carve-out exists precisely because the general rule is otherwise so broad.

Two more paragraphs shape the rest. Paragraph (b) deems a drug in package form misbranded unless it bears a label containing "the name and place of business of the manufacturer, packer, or distributor" and "an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count." Paragraph (c) governs prominence: a drug is misbranded if required information "is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use."

Paragraph (c) is the answer to a question people ask about fine print. A required statement that is technically present but visually buried is addressed by the statute itself, and the standard is what the ordinary individual is likely to read and understand under customary conditions of purchase and use.

The definition that tells you how misleading is judged

There is a further definition in section 321 that is easy to miss because it is not phrased as a definition. Subsection (n) says that where an article is alleged to be misbranded because the labeling or advertising is misleading, "there shall be taken into account (among other things) not only representations made or suggested by statement, word, design, device, or any combination thereof, but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result from the use of the article to which the labeling or advertising relates under the conditions of use prescribed in the labeling or advertising thereof or under such conditions of use as are customary or usual."

That sentence establishes two things. First, an omission counts. Whether something is misleading is judged partly by what it fails to reveal, not only by what it asserts. Second, the relevant conditions of use include not just those prescribed in the labeling but also those "customary or usual" — how the article is actually used, not only how it is described.

It is also the one provision in this group that mentions advertising in the same breath as labeling, which is why the two are often analyzed together even though they are separately defined and, in the drug context, administered under different regimes.

Where the regulations add specifics

Part 201 of Title 21 puts detail on these bones. Section 201.1 states that a drug or drug product in finished package form "is misbranded under section 502 (a) and (b)(1) of the act if its label does not bear conspicuously the name and place of business of the manufacturer, packer, or distributor," and then spends several paragraphs defining who may be represented as the manufacturer — a list of eleven operations, with rules for what to print when no single firm performs them all, such as "Made by (Person A), Filled by (Person B), Sterilized by (Person C)."

Section 201.6 addresses misleading statements directly, including the case of a multi-ingredient drug named in a way "which includes or suggests the name of one or more but not all such ingredients, even though the names of all such ingredients are stated elsewhere in the labeling." Stating the truth elsewhere does not cure a name that suggests something narrower.

Section 201.10 lists ways an ingredient statement can mislead, and the list is unusually specific. It names the order in which ingredients appear or their relative prominence; failure to reveal the proportion of an ingredient "when such proportion or other fact is material in the light of the representation that such ingredient is present"; use of a fanciful proprietary name implying unique effectiveness or composition when the ingredient is a common substance; and "The featuring in the labeling of inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role in the formulation."

One small provision is worth knowing because it corrects a widespread assumption. Section 201.2 says the National Drug Code number "is requested but not required to appear on all drug labels and in all drug labeling, including the label of any prescription drug container furnished to a consumer." A missing code is not, by itself, a labeling violation.

What this changes about reading a package or a page

The distinction between the two defined terms gives a reader a first question worth asking about any piece of paper or text: is this the container's own display, or is it material accompanying the article. The statute's definition of labeling covers both, and the misbranding standard applies to labeling as a whole rather than to the sticker alone.

It also reframes what counts as a problem. Under the omission clause, a statement can be accurate and the labeling still misleading, because the test takes account of facts material in light of the representations made. Under the prominence provision, information can be present and still fail, because the test is whether it is likely to be read and understood by an ordinary individual under customary conditions of purchase and use.

This site does not classify anyone's marketing material and takes no position on whether a particular web page is labeling — that question depends on facts about how the material is used and distributed. What the definitions supply is the vocabulary. When a document, an enforcement letter or a lawsuit uses the words label, labeling, misbranded, or in any particular, each of those words has a fixed statutory meaning that can be looked up rather than guessed at.